-
公开(公告)号：US09119883B2
公开(公告)日：2015-09-01
申请号：US14468672
申请日：2014-08-26
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram Shechter , Matityahu Fridkin , Haim Tsubery
IPC: A61K47/48 , A61K38/22 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12 , A61K38/26 , A61K38/28
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
362.发明申请INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE DISORDERS, CNS INJURY AND AGE-RELATED DEMENTIA 审中-公开中和神经损伤和年龄相关疾病的个体化免疫调节治疗公开(公告)号：US20150238582A1
公开(公告)日：2015-08-27
申请号：US14427089
申请日：2013-09-10
Inventor： Michal Eisenbach-Schwartz , Nir Friedman , Kuti Baruch , Gilad Kunis , Liora Cahalon , Neta Rosenzweig , Aleksandra Deczkowska
IPC: A61K39/00
CPC classification number: A61K39/0007 , A61K35/17 , A61K38/217 , A61K45/06 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61P25/28 , C07K16/2878 , C07K2317/76 , C12N5/0636 , C12N15/117 , C12N2310/17 , C12N2320/30 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2317 , C12N2501/24 , C12N2501/25 , A61K2300/00
Abstract: A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.
Abstract translation: 一种在有需要的受试者中治疗中枢神经系统（CNS）的疾病，病症，病症或损伤的方法，包括向所述受试者施用治疗有效量的活性成分，例如非脑炎性或弱致脑炎 Th1佐剂和CNS特异性抗原的组合，引起所述受试者的脉络丛的激活，并通过降低免疫抑制并在脉络丛上建立Th1型免疫应答来维持所述活化，从而允许抗炎免疫细胞或免疫细胞 其在脑脊液中获得愈合表型以通过脉络丛，并且在由所述疾病，病症，病状或损伤引起的CNS的损伤部位积聚。
-
363.发明申请CATALYTIC PROCESSES FOR OBTAINING INORGANIC NANOSTRUCTURES BY USING SOFT METALS 有权使用软金属获得无机纳米结构的催化工艺公开(公告)号：US20150225237A1
公开(公告)日：2015-08-13
申请号：US14635345
申请日：2015-03-02
Inventor： Reshef TENNE , Olga Brontvein , Jeffrey Gordon , Daniel Feuerman
CPC classification number: C01B19/007 , B82Y30/00 , C01B13/322 , C01B13/366 , C01G39/006 , C01G39/02 , C01G39/06 , C01G41/00 , C01G41/02 , C01P2002/54 , C01P2004/03 , C01P2004/04 , C01P2004/13 , C01P2004/16 , C01P2006/40 , C10M125/22 , C10M2201/065 , C10M2201/066 , H01B1/06 , H01B1/08 , H01B1/10
Abstract: The present invention concerns inorganic nanostructures comprising soft metals at low concentrations and catalytic processes utilizing soft metals for obtaining inorganic nanostructures.
Abstract translation: 本发明涉及包含低浓度的软金属和利用软金属获得无机纳米结构的催化方法的无机纳米结构。
-
364.发明申请公开(公告)号：US20150211041A1
公开(公告)日：2015-07-30
申请号：US14421834
申请日：2013-08-14
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Ehud Y. Shapiro , Tom Ran , Yehonatan Douek
Abstract: An autonomous synthetic programmable device adapted to determine a cell state according to one or more different predefined markers, comprising a transcription machinery and a regulatory element for regulating said transcription machinery, said regulatory element comprising at least three different binding regions, each binding region binding a different transcription factor and each binding region corresponding to a different predefined marker, wherein the regulatory element permits said transcription machinery to provide a transcription output if and only if all three different transcription factors are absent and wherein each transcription factor is capable of blocking transcription by said transcription machinery and hence blocking said transcription output.
Abstract translation: 一种自适应合成可编程装置，其适于根据一种或多种不同的预定义标记确定细胞状态，所述标记包含转录机制和用于调节所述转录机制的调节元件，所述调节元件包含至少三个不同的结合区，每个结合区结合 不同的转录因子和对应于不同的预定标记的每个结合区域，其中所述调节元件允许所述转录机制提供转录输出，如果并且仅当所有三种不同的转录因子都不存在并且其中每个转录因子能够通过所述转录因子阻断转录 转录机制，从而阻止转录输出。
-
365.发明申请THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS 审中-公开使用发展，人或猪，手术或手术的手术治疗方法公开(公告)号：US20150190546A1
公开(公告)日：2015-07-09
申请号：US14616837
申请日：2015-02-09
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Yair REISNER , Benjamin DEKEL , Smadar EVENTOV-FRIEDMAN , Helena KATCHMAN , Elias SHEZEN , Anna ARONOVICH , Dalit TCHORSH-YUTSIS
CPC classification number: A61L27/3604 , A61K35/22 , A61K35/407 , A61K35/54 , A61K39/39541 , A61K45/06 , A61L27/3641 , A61L27/54 , A61L2430/28 , A61K2300/00
Abstract: A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.
Abstract translation: 公开了在有需要的受试者中治疗肾，肝或酶缺乏障碍的方法。 该方法通过移植到源自人或猪，肾或肝，肾或肝处于选定妊娠阶段的受试组织中来实现。
-
Patent Agency Ranking
公开(公告)号：US20150157668A1
公开(公告)日：2015-06-11
申请号：US14627593
申请日：2015-02-20
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michael Walker , Yoav Soen , Revital Sharivkin
CPC classification number: A61K35/39 , C12N5/0676 , C12N2501/415 , C12N2501/50 , C12N2501/505 , C12N2501/585 , C12N2501/599 , G01N33/56966 , G01N2333/70596 , G01N2333/71 , G01N2500/10
Abstract: Methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of Langerhans. Markers and combinations thereof for use in methods of isolating insulin producing islet beta cells for treatment of diabetes.
Abstract translation: 在混合细胞群中分离不同特定细胞类型的方法。 在胰腺细胞，特别是胰岛细胞中分离特异性细胞类型的方法。 用于分离产生胰岛素胰岛β细胞用于治疗糖尿病的方法的标记物及其组合。
-
367.发明申请公开(公告)号：US20150132281A1
公开(公告)日：2015-05-14
申请号：US14398754
申请日：2013-05-09
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irit Sagi , Eitan Wong , Ran Afik
CPC classification number: A61K38/4886 , C12N9/6489 , C12Y304/24086 , Y02A50/473
Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
Abstract translation: 公开了一种治疗炎性疾病的方法。 该方法包括向受试者施用治疗有效量的包含TNF-α转换酶（TACE）的前域的多肽，所述多肽缺乏所述TACE的催化结构域，所述多肽在所选择的位点包含修饰 来自由R58，R56和K57组成的组，其使所述多肽对弗林蛋白酶降解具有抗性，所述多肽能够下调TACE的活性，从而治疗炎性疾病。
-
368.发明授权Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection 有权用于治疗和检测流感病毒感染的核酸分子，多肽，抗体和组合物公开(公告)号：US09029526B2
公开(公告)日：2015-05-12
申请号：US13680132
申请日：2012-11-19
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ruth Arnon , Sung-Ho Jeon , Basak Kayhan , Tamar Ben-Yedidia
IPC: C07H21/02 , C07H21/00 , A01N43/04 , A61K48/00 , C07H21/04 , C12N15/115 , G01N33/569
CPC classification number: C07H21/04 , C12N15/115 , C12N2310/16 , C12N2310/322 , G01N33/56983 , G01N2333/11
Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.
Abstract translation: 参与流感病毒感染细胞和核酸分子的多核苷酸和多肽，其包括能够特异性结合本发明多肽的多核苷酸序列。 还提供了使用这样的核酸分子，多核苷酸和针对其进行诊断，治疗和预防流感病毒感染的多核苷酸和抗体的方法。
-
369.发明授权PON polypeptides, polynucleotides encoding same and compositions and methods utilizing same 有权PON多肽，编码它们的多核苷酸以及使用它们的组合物和方法公开(公告)号：US09023631B2
公开(公告)日：2015-05-05
申请号：US14058334
申请日：2013-10-21
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Dan S. Tawfik , Amir Aharoni , Leonid Gaydukov , Joel L. Sussman , Israel Silman
CPC classification number: C12N9/18 , A61K38/00 , C12N9/16 , Y02A50/473
Abstract: Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes.
Abstract translation: 提供了分离的多核苷酸及其编码的多肽。 这些包括与相应的野生型PON相比具有增加的，修饰的或基本上相同的底物特异性的突变的PON酶。 还提供了使用这些酶的试剂盒和方法。
-
370.发明申请UNIVERSAL DONOR-DERIVED TOLEROGENIC CELLS FOR INDUCING NON-SYNGENEIC TRANSPLANTATION TOLERANCE 审中-公开用于诱导非同义转移耐受性的通用衍生的致癌细胞公开(公告)号：US20150104471A1
公开(公告)日：2015-04-16
申请号：US14578550
申请日：2014-12-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair REISNER
CPC classification number: A61K39/001 , A61K31/351 , A61K35/17 , A61K35/26 , A61K35/28 , A61K45/06 , A61K2039/5158
Abstract: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject
Abstract translation: 本发明提供了一种在有需要的受试者中通过非同基因移植物给药治疗疾病的方法，而不伴随或伴有伴随的移植排斥反应。 该方法包括向受试者施用与受试者非同基因的治疗有效的移植物，并且一定剂量的耐受性细胞与受试者和移植物不同，用于预防或减少受试者的移植物排斥，从而治疗疾病 在主题
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.071 seconds)
